Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia
Oncotarget. 2024 Apr 8;15:248-254. doi: 10.18632/oncotarget.28579.ABSTRACTAcute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include chemotherapy and bone marrow stem cell transplantation; however, they are often associated with poor prognosis. Notably, growth hormone-releasing hormone (GHRH) receptor antagonist MIA-602 has been shown to impede the growth of various human cancer cell lines, including AML. This investigation examined the impact of MIA-602 as monotherapy and in combination with Doxorubicin on three Doxorub...
Source: Oncotarget - April 8, 2024 Category: Cancer & Oncology Authors: Simonetta I Gaumond Rama Abdin Joel Costoya Andrew V Schally Joaquin J Jimenez Source Type: research
Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer
Oncotarget. 2024 Mar 19;15:238-247. doi: 10.18632/oncotarget.28567.ABSTRACTA clinical trial was conducted to assess the feasibility of enrolling patients with Stage II or III hormone receptor positive (HR+)/HER2-negative breast cancer to pre-operative dual PD-L1/CTLA-4 checkpoint inhibition administered prior to neoadjuvant chemotherapy (NACT). Eight eligible patients were treated with upfront durvalumab and tremelimumab for two cycles. Patients then received NACT prior to breast surgery. Seven patients had baseline and interval breast ultrasounds after combination immunotherapy and the responses were mixed: 3/7 patients e...
Source: Oncotarget - March 19, 2024 Category: Cancer & Oncology Authors: Haven R Garber Sreyashi Basu Sonali Jindal Zhong He Khoi Chu Akshara Singareeka Raghavendra Clinton Yam Lumarie Santiago Beatriz E Adrada Padmanee Sharma Elizabeth A Mittendorf Jennifer K Litton Source Type: research
